Equity intelligence report • July 05, 2026
Medtronic has reported a strong net income of $344 million for the quarter ending October 24, 2025, amidst global economic challenges and an estimated $185 million tariff impact for fiscal 2026. The company's solid operational performance is highlighted by net sales of $8.9 billion and a robust cash flow of $2 billion from operating activities. This comes as the company plans to spin off its Diabetes business into a new entity, MiniMed, aiming to adapt to changing market dynamics. Despite these successes, Medtronic has faced a decline in stock value due to broader market volatility, projecting ongoing challenges in the healthcare sector while striving to maintain financial stability and growth.
Click a month on the chart to update the report below.
